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Summary: HIV-positive people hospitalized with COVID-19 had an age-adjusted 47% higher risk 
of day-28 mortality compared with a large population of HIV-negative people within the same 
























Background Evidence is conflicting about how HIV modulates COVID-19. We compared the 
presentation characteristics and outcomes of adults with and without HIV who were 
hospitalized with COVID-19 at 207 centers across the United Kingdom and whose data were 
prospectively captured by the ISARIC WHO CCP study. 
Methods We used Kaplan-Meier methods and Cox regression to describe the association 
between HIV status and day-28 mortality, after separate adjustment for sex, ethnicity, age, 
hospital acquisition of COVID-19 (definite hospital acquisition excluded), presentation date, ten 
individual comorbidities, and disease severity at presentation (as defined by hypoxia or oxygen 
therapy). 
Results Among 47,592 patients, 122 (0.26%) had confirmed HIV infection and 112/122 (91.8%) 
had a record of antiretroviral therapy. At presentation, HIV-positive people were younger 
(median 56 versus 74 years; p<0.001) and had fewer comorbidities, more systemic symptoms 
and higher lymphocyte counts and C-reactive protein levels. The cumulative day-28 mortality 
was similar in the HIV-positive vs. HIV-negative groups (26.7% vs. 32.1%; p=0.16), but in those 
under 60 years of age HIV-positive status was associated with increased mortality (21.3% vs. 
9.6%; p<0.001 [log-rank test]). Mortality was higher among people with HIV after adjusting for 
age (adjusted hazard ratio [aHR] 1.47, 95% confidence interval [CI] 1.01-2.14; p=0.05), and the 



















p=0.008) and when restricting the analysis to people aged <60 years (aHR 2.87; 95% CI 1.70-
4.84; p<0.001). 
Conclusions HIV-positive status was associated with an increased risk of day-28 mortality among 
patients hospitalized for COVID-19.   
 





















Older age and presence of comorbidities including immunosuppression are recognized to 
increase the severity of COVID-19 [1-5]. However, existing evidence for an association between 
HIV infection and COVID-19 related outcomes is mixed. Despite effective antiretroviral therapy 
(ART), people with HIV (PWH) may continue to experience persistent immunodysfunction [6, 7] 
which might promote COVID-19 severity, or conversely, attenuate its pathological immune 
responses [8]. Although some antiretroviral drugs have been proposed to protect against 
COVID-19, the data remain uncertain [9,10]. Importantly, the common occurrence of co-factors 
such as diabetes and chronic renal and pulmonary disease [11], alongside disadvantageous 
socioeconomic variables [12], may increase the risk of adverse outcomes among PWH who 
acquire SARS-CoV-2. 
 
Several case series and observational cohort studies have described the outcomes of COVID-19 
in PWH across Europe [9,13-19], Asia [18,19], and the United States [8,18-22]. These studies 
have often been limited by small sample sizes, lack of direct comparative data from people 
without HIV, or inability to adjust for comorbidities. Some reports indicated that PWH did not 
experience higher rates of COVID-19 related hospitalization or mortality than people without 
HIV [14,21], whereas others suggested increased disease severity [9,20]. Importantly, 
preliminary data from South Africa indicated that despite effective ART, HIV infection more than 
doubled the risk of COVID-19 related mortality [23]. 
 
To characterize the presenting characteristics and outcomes of COVID-19 related hospitalization 



















within the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) 
WHO Clinical Characterization Protocol (CCP), the largest prospective observational study of 
patients admitted to hospital with COVID-19 worldwide [24].  
 
Methods 
Setting and participants   
The ISARIC WHO CCP-UK is an ongoing prospective cohort study in hospitals in England, 
Scotland, and Wales [24]. The study was activated on 17th January 2020. The protocol, case 
report form (CRF) and other study materials, and details of the Independent Data and Material 
Access Committee are available online *24+. Eligible patients were people aged ≥18 years who 
were admitted to participating hospitals (207 at the time of analysis) with either laboratory-
confirmed or highly likely (based on clinical, laboratory and radiological findings) SARS CoV-2 
infection. PCR-based virus detection was the only test available during the study and the 
decision to test was at the discretion of the attending clinical team, who also decided upon 
hospital admission, transfer into critical care and use of ventilation.   
 
Data collection  
Baseline was defined as the date of hospital admission or symptom onset (for those with 
symptom onset after hospitalization, see below). We included individuals with a baseline date 
that was on or before 4th June 2020 for whom  14 days had elapsed at data extraction on 18th 
June. Individuals with missing admission date were excluded. Where the date of symptom onset 



















Based on the date of symptom onset relative to the date of admission, the infection was classed 
as community-acquired (symptom onset <3 days), indeterminate (3-7 days), probable hospital-
acquired (8-14 days) and definite hospital-acquired (>14 days). Using the CRF version 9.2 [24], 
demographics, comorbidities and concomitant medications were recorded on admission; measures 
of disease severity and laboratory test results were recorded on day 1 (baseline), day 3, day 6, day 9 
and on the day of admission to critical care if applicable. CRF-reported HIV-positive status was 
confirmed via recorded ART, Pneumocystis jirovecii prophylaxis in the absence of non-HIV 
indications (n=2), or directly with a site investigator. Individuals with missing HIV status and 
those with unconfirmed HIV-positive status were excluded.  
 
Statistical analysis  
Presenting characteristics were compared between HIV-positive and HIV-negative people and 
between PWH who died and those who survived at 28 days using Wilcoxon rank sum tests (for 
continuous variables) and Pearson's chi-squared or Fisher’s exact test (for categorical variables). 
For all individuals, follow-up ended on the date of death. Patients discharged for home palliative 
care were considered to have died three days afterwards. Follow-up was right-censored at day 
28 for those remaining alive as an inpatient, or for those who were discharged (excepting 
palliative discharge) prior to day 28. No deaths were recorded among PWH after day 28. Follow-
up was censored for patients transferred to another facility at date of transfer; among those 
with unknown outcome, it was censored on the last recorded date of follow-up where they 
were known to be alive. For patients who died, were transferred or discharged on the date of 
admission or who had no further follow-up recorded beyond the first day, we recorded 0.5 days 



















mortality over this period and in strata defined by sex and age. Cox proportional hazards 
regression with the Efron method for ties was then used to describe the association of mortality 
with HIV status, before and after adjustment for the following potential confounders: sex, 
ethnicity, age (in quadratic form), indeterminate/probable hospital acquisition of COVID-19 (as 
defined above), and ten separate comorbidities at admission (a series of binary variables to 
indicate the presence or absence of each of chronic cardiac disease, chronic pulmonary disease, 
chronic renal disease, diabetes, obesity, chronic neurological disorder, dementia, liver disease 
[mild, moderate or severe], malignancy, and chronic hematological disease). These variables 
were selected a priori. We also included adjustment for the baseline date to account for 
changes in mortality over time. For partially missing comorbidity data, we assumed missing 
comorbidities were absent. Participants with completely missing comorbidity data were 
excluded from these adjusted analyses. We fitted a further model adjusting for disease severity 
a at presentation, defined as oxygen saturation <94% on air or receiving oxygen therapy, in 
order to assess whether risk of mortality in PWH could be explained by a different stage of 
disease advancement at hospitalization. Finally, we repeated the same analysis among 
individuals aged  70 year. A series of sensitivity analyses were performed: i) we repeated the 
analyses after censoring follow-up on the day of discharge; ii) we included those with definite 
hospital-acquired COVID-19;  iii) we used symptom onset date as the baseline date for all; iv) we 
excluded PWH lacking a record of ART; v) we excluded those without a recorded positive SARS-
CoV-2 PCR result; vi) we calculated propensity scores for HIV-positive status using a logistic 
regression model based on sex, ethnicity, age (in quadratic form), indeterminate/probable 
hospital acquisition of COVID-19, smoking status, baseline date, and ten comorbidities, and 
included the propensity score in a univariate Cox regression model for death at 28 days; vii) we 



















same confounder adjustment as described above); and viii) we used a competing risks 
regression model with discharge as a competing risk for mortality. In PWH, we used a Cox 
proportional hazard model to investigate associations with day-28 mortality. Analyses were 
conducted in Stata v16.1 (Statacorp, TX, USA). 
 
Ethical considerations  
Approval was granted by the following Ethics Committees: South Central-Oxford (Ref 
13/SC/0149), Scotland (Ref 20/SS/0028), and WHO (RPC571, RPC572). Data collection did not 




ISARIC CCP-UK recorded 53,993 people with COVID-19 between 17th January and 18th June 2020. 
After excluding non-eligible participants (Figure 1), we included 47,592 patients, of whom 122 
(0.26%) had confirmed HIV infection. A positive SARS-CoV-2 RNA PCR test was recorded for 
43,062/47,592 (90.5%) individuals. Patients excluded from the analysis did not differ by sex, 
ethnicity or age; in particular, the characteristics of those excluded due to missing HIV status 
closely resembled those reported to be HIV-negative (Supplementary Table 1). Among PWH, 
one person was diagnosed with HIV during the admission and 112 (91.8%) had an ART record. 
The regional distribution of study participants was similar to the UK population of PWH receiving 




















Characteristics at presentation 
PWH were younger than HIV-negative people (median 56 vs. 74 years, p<0.001) (Table 1, Figure 
2) and comprised a greater proportion of males and people of black ethnicity. PWH had fewer 
comorbidities overall, and a lower prevalence of cardiac, pulmonary and rheumatological 
disease, dementia, and malignancy, but higher rates of moderate/severe liver disease; 
proportions with chronic renal disease, diabetes and hematological disease were similar. The 
duration of symptoms was longer in PWH (median 5 vs. 3 days, p=0.002) (Table 2). PWH were 
more likely to present with fever, headache, myalgia and tachycardia, and to have cough and 
chest pain. Respiratory rate, occurrence of tachypnoea and hypoxia, and radiological evidence 
of chest infiltrates did not differ significantly between the two groups. PWH presented with 
lower total white blood cell and platelet count, but higher lymphocyte count and C-reactive 
protein (CRP) (Table 3).  
 
COVID-19 outcomes 
After adjustment for sex, ethnicity, age, baseline date, indeterminate/probable hospital 
acquisition of COVID-19, and ten comorbidities, the odds of admission to critical care were 
similar regardless of HIV status (odds ratio 1.22; 95% confidence interval [CI] 0.80-1.87; p=0.35) 
(Supplementary Table 3). By day 28 (Supplementary Table 4), 30 (24.6%) PWH were known to 
have died compared with 13,969 (29.4%) of the HIV-negative group; the cumulative incidence of 
day-28 mortality was 26.7% vs. 32.1%, respectively (p=0.16 Figure 3 A). Whilst findings were 
similar in men and women (Figure 3 B, C), univariate stratification for age revealed higher 



















years of age, mortality was 21.3% in HIV-positive patients versus 9.6% in HIV-negative patients 
(p<0.001). 
 
In the unadjusted analysis (Table 4), the cumulative hazard of day-28 mortality was lower in 
PWH (HR 0.77, 95% CI 0.54-1.11; p=0.17). Results did not change after adjusting for sex or 
ethnicity. In contrast, adjustment for age resulted in a change in the direction of the association 
(adjusted HR 1.47, 95% CI 1.01-2.14; p=0.05). Results were similar after adjustment for sex, 
ethnicity, age, baseline date, indeterminate/probable hospital acquisition of COVID-19 and ten 
comorbidities and following additional adjustment for disease severity at presentation. When 
restricted to people <60 years, the analysis yielded an adjusted HR of 2.87 (95% CI 1.70-4.86; 
p<0.001). Sensitivity analyses showed consistent results (Supplementary Table 5). In particular, 
censoring follow-up on the day of discharge, including definite hospital-acquired COVID-19, 
using symptom onset as baseline and excluding PWH lacking an ART record did not significantly 
alter the model. A separate logistic regression model with a binary variable of day-14 mortality 
and a competing risk regression model with discharge as a competing risk for mortality also 
showed increased odds of mortality in the HIV-positive group.  
 
 Among PWH, relative to patients who survived by day 28, patients who died were older and 
had a higher prevalence of diabetes and obesity and were less likely to have a record of ART 






















This study found evidence suggesting an age-adjusted 47% increased risk of day-28 mortality 
among PWH hospitalized with COVID-19 compared to HIV-negative individuals in the same 
dataset. Among people aged <60 years, HIV-positive status more than doubled the risk of 
mortality after adjusting for sex, ethnicity, age, baseline date, ten separate comorbidities, and 
disease severity at presentation (as indicated by a record of hypoxia or receiving oxygen 
therapy). The latter adjustment considered that doctors may be more likely to admit HIV-
positive adults with COVID-19 despite less severe symptoms.  
 
The influence of age, sex and ethnicity on COVID-19 outcomes is currently debated [1,2,25]. 
PWH in our study were significantly younger than the HIV-negative group and adjusting for age 
changed the direction of the association between HIV status and day-28 mortality, indicating 
that age was a significant confounder in our analyses. Men were more prevalent in the HIV-
positive group, which is consistent with the epidemiology of HIV infection in the UK, where men 
represent just over two thirds of the whole population with HIV [26]. People of black ethnicity 
comprised 42% of the HIV-positive group in this analysis relative to ~26% among PWH in the UK 
population [26]. Adjustment for sex or ethnicity alone did not impact our relative hazard 
estimates.  
 
Whilst there is a recognized interplay between HIV and comorbidities, neither omitting the 



















PWH had fewer comorbidities, notably lower prevalence of chronic pulmonary disease and 
malignancies, and this is largely a function of their younger age. HIV-positive people who died 
were older and were more likely to suffer from obesity and diabetes with complications than 
those who survived to discharge. Similar trends have been seen in the general population [1,25]. 
While these observations highlight the importance of obesity and diabetes as cofactors, the 
increased risk of COVID-19 related mortality in PWH was not merely due to the presence of 
promoting comorbidities. It should be highlighted that we did not take into consideration 
differences in the control of comorbidities between the two groups. 
 
Comparison with other studies 
Evidence about the interplay between HIV and COVID-19 is not entirely consistent [8,9,13-23]. A 
case-control study from New York compared 88 PWH, all of whom were receiving ART, and 405 
HIV-negative controls matched by age, gender, ethnicity, and calendar week of infection [21]. 
The study found no difference in the outcomes of COVID-19 related hospitalization after 
adjusting for demographics, chronic obstructive pulmonary disease, smoking, and baseline 
ferritin and white blood cell count. There are important differences in the two study 
populations. Participants in the New York study had a median age of 61 years (IQR 54-67), 
whereas we found excess mortality in HIV-positive people aged <60 years. Whereas 
malignancies were recorded less commonly in our cohort (3% vs. 10%), prevalence of obesity 
was higher (17% vs. 11%). It is also noteworthy that mortality in the overall ISARIC CCP-UK 
population was higher than that reported in the New York study [21] and other countries [1]. 
Consistent with our findings, there are preliminary data that HIV-positive status was associated 



















did not account for history of tuberculosis, obesity and socioeconomic status, it is noteworthy 
that HIV suppression on ART did not alter the mortality risk. 
 
Strengths and limitations of this study 
A key strength of this study was the ability to perform a direct comparison of people with and 
without HIV in the same dataset, and to account for age, gender, ethnicity and key 
comorbidities.  
The data for this study were collected during the first peak of the UK COVID-19 epidemic and 
there are missing data, including 2,742 patients with missing HIV status, who were excluded 
from the analysis. We also excluded 10 people initially recorded as having HIV but whose HIV 
status could not be confirmed; this group was similar to the HIV-negative group, with a median 
age of 81, suggesting that their initial HIV record was incorrect. Thus, these missing data are 
unlikely to affect the results.  
 
Our focus was on the effect of HIV-positive status on day-28 mortality among people 
hospitalized with COVID-19. We did not address risk factors for a COVID-19 diagnosis or 
hospitalization among PWH, or the suggested modulating role of certain antiretroviral agents 
[9,10]. We also lacked data to adjust for deprivation or socioeconomic status. Our analysis 
cannot provide evidence of the role of HIV-related parameters on outcomes of COVID-19 
related hospitalization, as we did not have details of the ART history, plasma HIV-1 RNA load, 
CD4 cell count, and history of HIV-related disease. HIV-positive people who died were less likely 



















the patients who died were not receiving ART, although this cannot be stated with certainty. In 
the UK, 93% of the 103,000 people estimated to have HIV infection have been diagnosed; of 
these, 97% receive ART with excellent virological suppression and only a small subset (~3%) is 
either not engaged with care or experiences problems with virological control despite ART [26]. 
Only a few PWH in our cohort had Pneumocystis jirovecii prophylaxis recorded in their admission 
medications, suggesting that the likelihood of PWH in our study being severely 
immunosuppressed was overall low.  
 
Despite effective ART and normalized CD4 cell counts, a subset of PWH continue to experience 
immune activation, inflammation and a pro-coagulatory state [7] which may modulate the risk 
of COVID-19 related morbidity and mortality [28,29]. Persistent immune dysfunction may be the 
consequence of advanced immunocompromise prior to the start of ART, as defined by a low 
nadir CD4 cell count and inverted CD4:CD8 ratio. In the UK, 43% of people newly diagnosed with 
HIV in 2018 had a CD4 count <350 cells/mm3, a threshold indicative of significant 
immunosuppression [26,30]. Furthermore, current guidelines about starting ART at the time to 
diagnosis were implemented relatively recently, whereas in the past ART initiation in the UK was 
deferred until the CD4 count had declined below thresholds of initially 200, then 350 and 
subsequently 500 cells/mm3 [6,30]. Thus, many older PWH in the UK (and worldwide) will have 
experienced years of uncontrolled HIV replication prior to commencing treatment and may also 
have received earlier regimens of suboptimal efficacy, with potentially lasting effects on 






















Our data are limited by the relatively small number of people with HIV included in the study and 
the findings should be interpreted with caution. Nonetheless, after careful considerations, our 
analysis of the outcomes of patients hospitalized with COVID-19 in the UK shows an increased 
risk of day-28 mortality due to HIV-positive status.  As the pandemic continues to spread, 
including in areas of increased HIV prevalence, it is important to record the HIV status of people 
hospitalized with COVID-19 and gather further data to corroborate our findings and confirm the 
population-specific determinants of outcomes. Meanwhile, emphasis for PWH should be placed 
on early HIV diagnosis, prompt ART initiation, and optimized screening for and control of 
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Age, median years (IQR) 56 (49, 62) 74 (60, 84) <0.001 
Age group,  
n (%) 
<40  7/120 (5.8) 2576/46 926 (5.5) <0.001 
40-49  26/120 (21.7) 3245/46 926 (6.9) 
50-59  48/120 (40.0) 5945/46 926 (12.7) 
60-69 26/120 (21.7) 7272/46 926 (15.5) 
≥70 13/120 (10.8) 27 888/46 
926 
(59.4) 





White 51/112 (45.5) 35 539/42 
208 
(84.2) <0.001 
Black 48/112 (42.9) 1475/42 208 (3.5) 
Asian 1/112 (0.9) 2249/42 208 (5.3) 
Other 12/112 (10.7) 2945/42 208 (7.0) 
Smoking,  
n (%) 
Never  65/94 (69.2) 17 396/30 
379 
(57.3) 0.004 
Former 18/94 (19.2) 10 634/30 
379 
(35.0) 
Current 11/94 (11.7) 2340/30 379 (7.7) 
Comorbidities, median number (IQR) 1 (1, 2) 2 (1, 3) <0.001 
Comorbidities,  
n (%) 
None 31/122 (25.4) 9679/46 742 (20.7) <0.001 
1 50/122 (41.0) 13 544/46 
742 
(29.0)  






































13/120 (10.8) 8055/44 918 (17.9) 0.04 
Asthma 12/116 (10.3) 6239/44 758 (13.9) 0.26 
Chronic renal disease 21/116 (18.1) 7874/44 728 (17.6) 0.89 
Diabetes, no complications 16/117 (13.7) 7783/43 862 (17.7) 0.25 
Diabetes, with 
complications 
9/117 (7.7) 3308/43 587 (7.6) 0.97 
Obesity 19/112 (17.0) 4597/40 458 (11.4) 0.06 
Chronic neurological 
disorder 
8/116 (6.9) 5588/44 478 (12.6) 0.07 
Dementia 3/118 (2.5) 7464/44 554 (16.8) <0.001 
Mild liver disease 3/118 (2.5) 632/44 228 (1.4) 0.24 
Moderate/severe liver 
disease 
6/118 (5.1) 861/44 281 (1.9) 0.01 
Malignancy 4/118 (3.4) 4598/44 359 (10.4) 0.009 
Chronic hematological 
disease 
4/118 (3.4) 1931/44 311 (4.4) 0.82 
Rheumatological disease 6/118 (5.1) 4874/44 183 (11.0) 0.04 
Malnutrition 5/112 (4.5) 1133/41 853 (2.7) 0.23 



















Table 2. Presenting symptoms and observations, stratified by HIV status 
 









Fever 99/120 (82.5) 30 650/47 
085 
(65.1) <0.001 
Myalgia 28/104 (26.9) 6351/34 839 (18.2) 0.02 
Headache 18/96 (18.8) 3661/34 790 (10.5) 0.009 
Cough 96/121 (79.3) 31 028/47 
077 
(65.9) 0.002 
Dyspnea 88/121 (72.7) 32 141/47 
043 
(68.3) 0.30 
Chest pain 25/109 (22.9) 5227/38 302 (13.7) 0.005 
Sore throat 14/100 (14.0) 2806/34 294 (8.2) 0.03 
Wheeze 6/102 (5.9) 3293/36 241 (9.1) 0.26 
Rhinorrhea 3/97 (3.1) 831/33 562 (2.5) 0.52 
Diarrhea 28/108 (25.9) 7277/39 340 (18.5) 0.05 
Nausea or vomiting 23/105 (21.9) 7650/39 560 (19.3) 0.51 
Abdominal pain 13/104 (12.5) 4033/38 136 (10.6) 0.52 
Fatigue 43/98 (43.9) 16 111/37 
202 
(43.3) 0.91 




Systemic 108/121 (89.3) 32 267/47 
119 
(68.5) <0.001 
Respiratory 108/121 (88.5) 38 736/47 
158 
(82.1) 0.04 





















Symptom duration, median days (IQR) 5 (1, 9) 3 (0, 7) 0.002 
Symptom 
onset b,  
n (%) 
<3 days 114/122 (93.4) 41 285/47 
101 
(87.7) 0.20 
3-7 days 1/122 (0.8) 1488/47 101 (3.2) 
8-14 days  4/122 (3.3) 1603/47 101 (3.4) 
>14 days 3/122 (2.5) 2725/47 101 (5.8) 
Presenting 
signs 





Fever ≥37.8 °C, n (%) 60/117 (51.3) 16 447/45 
458 
(36.2) 0.001 
HR, median beats/min (IQR) 96 (81, 110) 90 (78, 105) 0.004 
Tachycardiac, n (%) 52/117 (44.4) 15 076/45 
432 
(33.2) 0.01 
RR, median breaths/min (IQR) 20 (18, 27) 21 (18, 26) 0.97 
Tachypnead, n (%) 55/114 (48.3) 23 306/45 
209 
(51.6) 0.48 
Hypoxiae/on oxygen, n (%) 56/115 (48.7) 23 971/45 
242 
(53.0) 036 
Infiltrates visible on CXR, n (%) 49/74 (66.2) 19 065/30 
566 
(62.4) 0.50 




130 (114, 147) 0.78 
Diastolic BP, median mmHg 
(IQR) 
80 (68, 86) 74 (65, 84) 0.007 
aSystemic symptoms: ≥1 of fever, myalgia or headache; Respiratory symptoms: ≥1 of cough, 
dyspnea, chest pain, sore throat, wheeze; Gastrointestinal symptoms: ≥1 of: Diarrhea, nausea, 
vomiting or abdominal pain.  bBased on the onset of symptoms relative to the date of admission, 
COVID-19 acquisition was classed as community (<3 days), indeterminate (3-7 days), probable 
hospital (8-14 days), and definite hospital (>14 days). cDefined as HR >100 beats/min. dDefined as 
RR >20 breaths/min. eDefined as SpO2 <94% on air. Abbreviations: IQR, Interquartile range; HR, 























Table 3. Presenting laboratory parameters, stratified by HIV status 
 





Hemoglobin, median g/L (IQR) 130 (117, 145) 129 (113, 143) 0.56 
Anemiaa, n (%)  39/107 (36.5) 15 570/40 
092 
(38.8) 0.61 
WBC, median count x109/L (IQR) 6.6 (4.8, 9.1) 7.4 (5.4, 10.4) 0.01 
Lymphocytes, median count x109/L 
(IQR) 
1.0 (0.8, 1.5) 0.9 (0.6, 1.3) <0.001 
Lymphopeniab, n (%) 51/108 (47.2) 23 014/39 
759 
(57.9) 0.03 
Platelets, median count x106/L (IQR) 197 (150, 258) 217 (164, 286) 0.01 
Thrombocytopeniac, n (%) 26/105 (24.8) 7440/39 739 (18.7) 0.11 
Prothrombin time, median sec (IQR) 13.6 (11.0, 15.0) 13.2 (11.8, 15.0) 0.58 
Creatinine, median µmol/L (IQR) 89 (72, 134) 86 (67, 121) 0.26 




≥60 68/100 (68.0) 24 783/38 
821 
(63.8) 0.15 
30-59 21/100 (21.0) 9786/38 821 (25.2) 
15-29 4/100 (4.0) 2846/38 821 (7.3) 
<15 7/100 (7.0) 1406/38 821 (3.6) 



















ALT >40 U/L, n (%) 28/89 (31.5) 8458/30 478 (27.8) 0.44 
Glucose, median mmol/L IQR) 6.8 (5.8, 10.3) 6.8 (5.8, 8.9) 0.44 
Hyperglycemiae, n (%) 11/54 (20.4) 2903/19 541 (14.9) 0.26 
C-reactive protein, median mg/L 
(IQR) 
107 (51, 200) 83 (36, 157) 0.02 
aDefined as hemoglobin <130 g/L in males and <115 g/L in females. bDefined as lymphocyte 
count <1.0 x109/L. cDefined as platelet count <150 x106/L. dBased on the Modification of Diet in 
Renal Disease (MDRD) formula where eGFR (mL/min/1.73 m²) = 175 × (Scr/88.4)-1.154 × (Age)-
0.203 × (0.742 if female) × (1.212 if Black ethnicity). eDefined as glucose >11 mmol/L. 
Abbreviations: IQR, Interquartile range; Abbreviations: IQR, Interquartile range; WBC, White 



















Table 4. Cox proportional hazards model of the association between HIV status and day-28 
mortality 
 
HIV-positive versus HIV-negative  
 
Hazard ratio 95% CI P value 
Unadjusted 0.77 0.54 to 1.11 0.17 
Adjusted for sex 0.76 0.53 to 1.10 0.15 
Adjusted for ethnicity 0.88 0.60 to 1.29 0.52 
Adjusted for age 1.47 1.01 to 2.14 0.05 
Adjusted for age and sex 1.45 1.00 to 2.12 0.05 
Adjusted for sex, ethnicity, age, baseline date, and 
indeterminate/probable hospital acquisition of COVID-
19 
1.49 1.01 to 2.20 0.04 
Adjusted for sex, ethnicity, age, baseline date, 
indeterminate/probable hospital acquisition of COVID-
19, and 10 comorbiditiesa 
1.50 1.02 to 2.22 0.04 
Adjusted for sex, ethnicity, age, baseline date, 
indeterminate/probable hospital acquisition of COVID-
19, 10 comorbiditiesa, and hypoxia/receiving oxygen at 
presentationb 
1.69 1.15 to 2.48 0.008 
Adjusted for sex, ethnicity, age, baseline date, 
indeterminate/probable hospital acquisition of COVID-
19, 10 comorbiditiesa and hypoxia/receiving oxygen at 
presentationb among individuals aged <60 years 
2.87 1.70 to 4.86 <0.001 
 
aThe model adjusted separately for the following comorbidities: chronic cardiac disease, 
chronic pulmonary disease, chronic renal disease, diabetes, obesity, chronic 
neurological disorder, dementia. liver disease, malignancy, and chronic hematological 
disease. bHypoxia was defined as SpO2 <94% on air; a record of hypoxia or receiving 




















Table 5. Characteristics of patients with HIV, stratified by outcome at day 28, selected variablesa  
 
Characteristic Died n=30 Alive n=92 P-
value 
Age, median years (IQR) 58 (55, 70) 55 (49, 61) 0.01 
Age group,  
n (%) 
<40  1/28 (3.6) 6/92 (6.5) 0.12 
40-49  4/28 (13.8) 22/92 (23.9) 
50-59  10/28 (37.9) 38/92 (41.3) 
60-69 6/28 (20.7) 20/92 (21.7) 
≥70 7/28 (24.1) 6/92 (6.5) 
ART recorded, n 
(%) 




Chronic pulmonary diseaseb 1/29 (3.5) 12/91 (13.2) 0.19 
Diabetes, with complications 5/30 (16.7) 4/87 (4.6) 0.03 




Cough 26/29 (89.7) 70/92 (76.1) 0.19 
Diarrhea 8/26 (30.8) 20/82 (24.4) 0.52 
Symptom group, n 
(%) 
Respiratoryc 28/29 (96.6) 80/92 (87.0) 0.19 
Presenting 
signs 
HR, median beats/min (IQR) 106 (95, 121) 92  (80, 108) 0.003 
Tachycardiad, n (%) 16/27 (59.3) 36/90 (40.0) 0.08 
RR, median breaths/min (IQR) 26 (20, 30) 20 (18, 24) 0.006 
Tachypneae, n (%) 18/27 (66.7) 37/87 (42.5) 0.03 
Hypoxiaf/on oxygen, n (%) 22/28 (78.6) 34/87 (39.1) <0.001 
Laboratory 
parameters 
WBC, median count x109/L (IQR) 8.0 (5.4, 11.8) 5.6 (4.6, 8.7) 0.02 
eGFRg, median ml/min/1.73m2 
(IQR) 



















Glucose, median mmol/L (IQR) 10.4 (6.4, 
13.2) 
6.4 (5.8, 8.3) 0.02 
Hyperglycemiah, n (%) 6/15 (40.0) 5/39 (12.8) 0.05 
C-reactive protein, median mg/L 
(IQR) 
187 (97, 252) 92 (40, 157) 0.001 
Interventions, n (%) Oxygen therapy during admission 22/30 (73.3) 54/87 (62.1) 0.27 
 Critical care admission 20/30 (66.7) 19/92 (20.7) <0.001 
 Non-invasive ventilation 12/27 (44.4) 16/87 (18.4) 0.006 
 Invasive ventilation 13/29 (44.8) 6/87 (6.9) <0.001 
aA full list of demographic and clinical characteristics is shown in Supplementary Table 6. 
bExcludes asthma. cRespiratory symptoms: ≥1 of cough, dyspnea, chest pain, sore throat, 
wheeze. dDefined as HR >100 beats/minute. eDefined as RR >20 breaths/min. fDefined as SpO2 
<94% on air. gBased on the Modification of Diet in Renal Disease (MDRD) formula where eGFR 
(mL/min/1.73 m²) = 175 × (Scr/88.4)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if Black 
ethnicity). hDefined as glucose >11 mmol/L.  Abbreviations: IQR, Interquartile range; ART, 
Antiretroviral therapy; HR, Heart rate; RR, Respiratory rate; BP, Blood pressure; WBC, White 






















LEGENDS TO FIGURES 
Figure 1. Flowchart of study participants. 
Figure 2. Kernel density plot of age distribution of study participants stratified by HIV status.  
Figure 3. Kaplan Meier survival plots stratified by HIV status. A: All, B: Female, C: Male D: <50 
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Figure 1: Flowchart of study participants 
aHIV status was confirmed if participants were recorded as receiving antiretroviral therapy or prophylaxis against 
Pneumocystis jirovecii, or if local site investigators were able to confirm HIV status. 
ISARIC CCP participants  
with COVID-19 
at analysis date  
18th June 2020 
n=53,993 
Excluded 
 Missing HIV status, n=2,742 
 Missing admission date, n=2,694 
 Children <18 years, n=652 
 Admission or symptom onset date  
 >4th June 2020, n= 303 
 Unable to confirm HIV statusa,   n=10
 
Participants included in analysis, 
n=47,592 
 People living with HIV, n=122
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